What it is and what it is used for

for The name of your medicine is Cyclizine Lactate Injection. Cyclizine Lactate Injection contains the active substance cyclizine lactate, which belongs to a group of medicines called antihistamines which can be used to help stop you feeling sick (nausea) or being sick (vomiting). Cyclizine lactate Injection may be used by adults. Cyclizine lactate Injection may be used if you suffer from travel or motion sickness; nausea caused by cancer treatment (radiotherapy) or other medicines; or if you have had an operation, as general anaesthetics can sometimes cause sickness. Cyclizine lactate Injection can also be used to treat sickness caused by some inner ear problems such as Meniere's disease.

What you need to know before you take it

Cyclizine Lactate Injection Do not use this medicine: if you are allergic to cyclizine lactate or any of the other ingredients of this medicine (listed in section 6)  if you have allergic reactions which include mild symptoms such as itching and/or rash. More severe symptoms include swelling of the face, lips, tongue and/or throat with difficulty in swallowing or breathing  if you have been drinking alcohol. The anti-vomiting properties of Cyclizine lactate Injection may increase the toxicity of alcohol. Warnings and precautions Talk to your doctor or nurse before you are given Cyclizine lactate Injection if you:

          

suffer from an eye disease caused by a rise of pressure within the eye (glaucoma) suffer from urinary retention (experience difficulty passing urine) have an obstructive bowel condition have any liver problems suffer from phaeochromocytoma (tumour of the medulla of the adrenal glands) suffer from high blood pressure have epilepsy are a man and you suffer from an enlarged prostate gland (difficulty or slowness passing urine) have been told your heart is not working properly (heart failure) suffer from an inherited disorder which can lead to a sensitivity to sunlight (porphyria) suffer from low blood pressure.

Other medicines and Cyclizine lactate Injection Tell your doctor if you are taking any other medicines especially the following:  medicines for problems such as depression, anxiety or difficulty in sleeping  strong painkillers such as pethidine  any medicine which belong to a group of medicines called anticholinergics. Please tell your doctor if you are taking or have recently taken any other medicines including those you have obtained without a prescription. Cyclizine lactate Injection with food, drink and alcohol Alcohol should be avoided when you are being treated with Cyclizine lactate Injection. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine. Driving and using machines You can drive while being treated with Cyclizine lactate Injection but do not drive until you know how it affects you. It may make you feel dizzy. If it affects you in this way, do not drive or operate any machinery.

How to take it

to you You will be given Cyclizine lactate Injection under supervision and your doctor will decide on a dose which is right for you. Cyclizine lactate Injection can be given as a slow injection into a vein (intravenously) or by injection into a muscle (intramuscularly). The recommended dose for adults is:  50 mg up to three times a day. For prevention of sickness after a normal operation: Your doctor will give the first dose of Cyclizine lactate by injection into a vein, approximately 20 minutes before the end of the operation. The use of the injectable form of cyclizine has been

associated with cases of transient paralysis following administration of the medicine. The onset of paralysis is usually within minutes of administration, affects the limbs, and fully resolves within hours of discontinuation of the medicine. If you receive more Cyclizine lactate Injection than you should As this medicine is given to you by a doctor, it is very unlikely that an overdose will happen. Should an overdose occur, the doctor will treat any symptoms that follow. Symptoms of overdose include dry mouth, nose and throat, blurred vision, fast or irregular heartbeat, difficulty passing urine, drowsiness, dizziness, lack of balance and coordination, weakness, excitability, disorientation, impaired judgement, hallucinations, muscle spasm, involuntary movements, convulsions, high temperature and difficulty breathing. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. If you notice:

• itching or skin rashes
• swelling of the face, lips or throat
• difficulty in breathing or wheeziness. Tell your doctor immediately. These may be signs of an allergic reaction. The following side effects are reported for either compound with a not known frequency (frequency cannot be estimated from the available data)

Possible side effects

may include:  skin rashes or itching  muscle twitches, spasms or tremors  restlessness  decrease in muscle tone that can cause irregular body movements  unusual body movements, particularly of your hands, arms or legs  lack of coordination  blurred vision or involuntary rolling of the eyes  paralysis especially in patient who are already suffering from disorder of nerves and muscles  convulsions, seizures  nervousness  seeing or hearing things that are not really there (hallucinations)  ringing in the ears  euphoria  headache  fast heartbeat, irregular heartbeat  drowsiness or general feelings of weakness/tiredness  a dry mouth, nose or throat  heartburn (reflux)  stomach pain  nausea  vomiting

                   

diarrhoea loss of appetite difficulty in passing water constipation difficulty in sleeping being confused, disorientated or unaware dizziness decreased consciousness/loss of consciousness temporary difficulty in speaking high blood pressure low blood pressure pins and needles yellowing of the skin and the whites of your eyes (jaundice) a red or brownish patch which appears at the same spot each time you take the medicine inflammation of the liver (hepatitis) or problems with the liver injection site reactions such as redness, pain, swelling or blistering sensations of heaviness, flushing, feeling cold or agitated or experiencing a decrease in blood pressure reduced rate of breathing (apnoea) reduction in the production of a type of white blood cell making infection more likely (agranulocytosis) unpleasant sensation or an overwhelming urge to move the legs (also called Restless Legs Syndrome).

If you feel very tired, experience unexpected bruising or bleeding or more infections (e.g. colds and sore throats) than usual, please tell your doctor. Your doctor may decide to conduct tests on your blood periodically as a result of these symptoms. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By Reporting side effects, you can help provide more information on the safety of this medicine.

How to store it

Cyclizine Lactate Injection Keep this medicine out of the sight and reach of children. Cyclizine lactate Injection will be stored by the hospital pharmacy before it is given to you. They will follow the instructions below. Cyclizine lactate Injection should be stored in a safe place below 25°C and protected from light. The injection should not be used if there are any particles floating in it or after the "EXP" date on the carton and label.

Contents of the pack and other information

What Cyclizine lactate Injection contains Cyclizine lactate Injection comes as a 1 ml ampoule containing 50 mg of the active ingredient, cyclizine lactate, dissolved in sterile water.

The injection also contains the inactive ingredient, lactic acid. What Cyclizine lactate Injection looks like and contents of the pack Cyclizine lactate Injection is a clear, colourless solution. Each pack contains 5 ampoules. Marketing Authorisation Holder Amdipharm UK Limited, Dashwood House, 69 Old Broad Street, London, EC2M 1QS, United Kingdom

Alternative Manufacturer Cenexi, 52 Rue Marcelet Et Jacques Gaucher, Fontenay-Sous Bois, F-94120, France This leaflet was last revised in January 2024.

———————————————————————————————————————————

SUMMARY OF PRODUCT CHARACTERISTICS

1.

NAME OF THE MEDICINAL PRODUCT Valoid 50 mg/ml Injection Cyclizine Lactate 50 mg/ml Injection

2.

QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml ampoule contains 50 mg cyclizine lactate. For the full list of excipients, see section 6.1.

3.

PHARMACEUTICAL FORM Clear, colourless solution for injection.

4.

CLINICAL PARTICULARS

4.1.

Therapeutic indications Cyclizine Lactate Injection is indicated in adults for the prevention and treatment of nausea and vomiting including:   

Motion sickness when the oral route cannot be used. Nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period. Vomiting associated with radiotherapy especially for breast cancer since cyclizine does not elevate prolactin levels.



Cyclizine Lactate injection, by the intravenous route, is also indicated preoperatively in patients undergoing emergency surgery in order to reduce the hazard of regurgitation and aspiration of gastric contents during induction of general anaesthesia. Cyclizine Lactate Injection may be of value in relieving vomiting and attacks of vertigo associated with Menière's disease and other forms of vestibular disturbance when the oral route cannot be used. 4.2.

Posology and method of administration Posology For the prevention of postoperative nausea and vomiting, administer the first dose by slow intravenous injection 20 minutes before the anticipated end of surgery. Adults 50 mg intramuscularly or intravenously up to three times daily. When used intravenously, Cyclizine Lactate Injection should be injected slowly into the bloodstream, with only minimal withdrawal of blood into the syringe. For the prevention of postoperative nausea and vomiting, administer the first dose by slow intravenous injection 20 minutes before the anticipated end of surgery. Cyclizine given intravenously, in half the recommended dose, increases the lower oesophageal sphincter tone and thereby reduces the hazard of regurgitation and aspiration of gastric contents if given to patients, undergoing emergency surgery, before induction of general anaesthesia. Elderly There have been no specific studies of Cyclizine Lactate Injection in the elderly. Experience has indicated that normal adult dosage is appropriate. Paediatric population Not licensed for use in children. Method of Administration: Intramuscularly or intravenously.

4.3.

Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cyclizine Lactate is contraindicated in the presence of acute alcohol intoxication. The antiemetic properties of cyclizine may increase the toxicity of alcohol.

4.4.

Special warnings and precautions for use As with other anticholinergic agents, Cyclizine Lactate Injection may precipitate incipient glaucoma and it should be used with caution and appropriate monitoring in patients with glaucoma, urinary retention, obstructive disease of the gastrointestinal tract, hepatic disease, pheochromocytoma, hypertension, epilepsy and in males with possible prostatic hypertrophy. Cyclizine Lactate Injection may have a hypotensive effect. Cyclizine should be used with caution in patients with severe heart failure or acute myocardial infarction. In such patients, cyclizine may cause a fall in cardiac output associated with increases in heart rate, mean arterial pressure and pulmonary wedge pressure. Cyclizine should be avoided in porphyria. There have been reports of abuse of cyclizine, either oral or intravenous, for its euphoric or hallucinatory effects. The concomitant misuse of Cyclizine Lactate Injection with large amounts of alcohol is particularly dangerous, since the antiemetic effect of cyclizine may increase the toxicity of alcohol (see also Section 4.5). Case reports of paralysis have been received in patients using intravenous cyclizine. Some of the patients mentioned in these case reports had an underlying neuromuscular disorder. Thus intravenous cyclizine, should be used with caution in all patients and with particular care in patients with underlying neuromuscular disorders.

4.5.

Interactions with other medicinal products and other forms of interaction Cyclizine Lactate may have additive effects with alcohol and other central nervous system depressants e.g. hypnotics, tranquillisers, anaesthetics, antipsychotics, barbiturates. Cyclizine Lactate enhances the soporific effect of pethidine. Cyclizine Lactate may counteract the haemodynamic benefits of opioid analgesics. Because of its anticholinergic activity, cyclizine may enhance the side-effects of other anticholinergic drugs, and may have an additive antimuscarinic action with other antimuscarinic drugs, such as atropine and some antidepressants (both tricyclics and MAOIs). Cyclizine Lactate may mask the warning signs of damage caused by ototoxic drugs such as aminoglycoside antibacterials.

4.6.

Fertility, pregnancy and lactation Pregnancy

In the absence of any definitive human data, the use of Cyclizine Lactate in pregnancy is not advised. Breast-feeding Cyclizine is excreted in human milk, however, the amount has not been quantified. Fertility: In a study involving prolonged administration of cyclizine to male and female rats, there was no evidence of impaired fertility after continuous treatment for 90-100 days at dose levels of approximately 15 and 25 mg/kg/day. There is no experience of the effect of Cyclizine Lactate on human fertility. 4.7

Effects on ability to drive and use machines Studies designed to detect drowsiness did not reveal sedation in healthy adults who took a single oral therapeutic dose (50 mg) of cyclizine, sedation of short duration was reported by subjects receiving intravenous cyclizine. Patients should not drive or operate machinery until they have determined their own response. Although there are no data available, patients should be cautioned that Cyclizine Lactate Injection may have additive effects with alcohol and other central nervous system depressants, e.g. hypnotics and tranquillisers.

4.8.

Undesirable effects Adverse reactions are ranked under heading of frequency, the most frequent first, using the following convention: Very common: (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000); Not known: cannot be estimated from the available data. The following undesirable effects have been reported with a frequency of Not known. System Organ Class Frequency Blood and lymphatic Not known system disorders

Adverse reactions Agranulocytosis, leucopenia, haemolytic anaemia, thrombocytopenia.

Cardiac disorders

Not known

Ear and labyrinth disorders Not known

Tachycardia palpitations, arrhythmias (see section 4.4)

Tinnitus. There have been rare case reports of patients experiencing depressed levels of consciousness/loss of consciousness.

Eye disorders

Gastrointestinal disorders

Not known

Blurred vision, oculogyric crisis

system Not known

Dryness of the mouth, nose and throat, constipation, increased gastric reflux, nausea, vomiting, diarrhoea, stomach pain, loss of appetite.

General disorders administration conditions

and Not known site

Asthenia, malaise Injection site reactions including vein tracking, erythema, pain, thrombophlebitis and blisters. A sensation of heaviness, chills, flushing, agitation and pruritus have been reported rarely.

Rapid IV administration can lead to symptoms similar to overdose. Hepatobiliary disorders

Not known

Hepatic dysfunction (see section 4.4), hypersensitivity hepatitis,

cholestatic jaundice and cholestatic hepatitis have occurred in association with cyclizine. Immune system disorders

Not known

Hypersensitivity reactions, including anaphylaxis have occurred.

Musculoskeletal and Not known connective tissue disorders

Twitching, muscle spasms

Nervous system disorders

Not known

Effects on the central nervous system have been reported with cyclizine these include somnolence, drowsiness, incoordination, headache, dystonia, dyskinesia, extrapyramidal motor disturbances, restless leg syndrome, tremor, convulsions, dizziness, decreased consciousness, transient speech disorders, paraesthesia, paralysis* and generalised chorea.

Psychiatric disorders

Not known

Disorientation, restlessness or agitation, nervousness, euphoria, insomnia and auditory and visual hallucinations have been reported, particularly when dosage recommendations have been exceeded.

Renal and urinary disorders Not known

Urinary retention

Respiratory, thoracic and Not known mediastinal disorders

Bronchospasm, apnoea

Skin and subcutaneous Not known tissue disorders

Urticaria, pruritus, drug rash, angioedema, allergic skin reactions, fixed drug eruption, photosensitivity

Vascular disorders

Hypertension, hypotension

Not known

*Case reports of paralysis have been received in patients using intravenous cyclizine. Some of the patients mentioned in these case reports had an underlying neuromuscular disorder. (see section 4.4)

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. 4.9.

Overdose Symptoms Symptoms of acute toxicity from cyclizine arise from peripheral anticholinergic effects and effects on the central nervous system. Peripheral anticholinergic symptoms include, dry mouth, nose and throat, blurred vision, tachycardia and urinary retention. Central nervous system effects include drowsiness, dizziness, incoordination, ataxia, weakness, hyperexcitability, disorientation, impaired judgement, hallucinations, hyperkinesia, extrapyramidal motor disturbances, convulsions, hyperpyrexia and respiratory depression. An oral dose of 5 mg/kg is likely to be associated with at least one of the clinical symptoms stated above. Younger children are more susceptible to convulsions. The incidence of convulsions, in children less than 5 years, is about 60% when the oral dose ingested exceeds 40 mg/kg. Management In the management of acute overdosage with Cyclizine Lactate Injection, gastric lavage and supportive measures for respiration and circulation should be performed if necessary. Convulsions should be controlled in the usual way with parenteral anticonvulsant therapy.

5.

PHARMACOLOGICAL PROPERTIES

5.1.

Pharmacodynamic properties Pharmacotherapeutic Group: Piperazine derivatives ATC Code: R06AE03

Mechanism of action: Cyclizine is a histamine H1 receptor antagonist of the piperazine class which is characterised by a low incidence of drowsiness. It possesses anticholinergic and antiemetic properties. The exact mechanism by which cyclizine can prevent or suppress both nausea and vomiting from various causes is unknown. Cyclizine increases lower oesophageal sphincter tone and reduces the sensitivity of the labyrinthine apparatus. It may inhibit the part of the midbrain known collectively as the emetic centre. Pharmacodynamics effects: Cyclizine produces its antiemetic effect within two hours and lasts approximately four hours. 5.2.

Pharmacokinetic properties Distribution In healthy adult volunteers the administration of a single oral dose of 50 mg cyclizine resulted in a peak plasma concentration of approximately 70 ng/ml occurring at about two hours after drug administration. The plasma elimination half-life was approximately 20 hours. Biotransformation The N-demethylated derivative, norcyclizine, has been identified as a metabolite of cyclizine. Norcyclizine has little antihistaminic (H1) activity compared to cyclizine and has a plasma elimination half life of approximately 20 hours. Elimination After a single dose of 50mg cyclizine given to a single adult male volunteer, urine collected over the following 24 hours contained less than 1% of the total dose administered.

5.3.

Preclinical safety data

A. Mutagenicity Cyclizine was not mutagenic in a full Ames test, including use of S9-microsomes but can nitrosate in vitro to form mutagenic products. B. Carcinogenicity No long term studies have been conducted in animals to determine whether cyclizine has a potential for carcinogenesis. However, long-term studies with cyclizine administered with nitrate have indicated no carcinogenicity. C. Teratogenicity Some animal studies are interpreted as indicating that cyclizine may be teratogenic at dose levels up to 25 times the clinical dose level. In another study, cyclizine was negative at oral dose levels up to 65 mg/kg in rats and 75 mg/kg in rabbits. The relevance of these studies to the human situation is not known. D. Fertility In a study involving prolonged administration of cyclizine to male and female rats there was no evidence of impaired fertility after continuous treatment for 90-100 days at dose levels of approximately 15 and 25 mg/kg/day. There is no experience of the effect of Cyclizine on human fertility. 6.

PHARMACEUTICAL PARTICULARS

6.1.

List of excipients Lactic Acid Water for Injections

6.2.

Incompatibilities None known. In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3.

Shelf life 2 years.

6.4.

Special precautions for storage Store below 25oC Protect from light, keep the ampoule in the outer carton.

6.5.

Nature and contents of container 1ml neutral glass ampoules. Five ampoules in a carton.

6.6.

Special precautions for disposal No special requirements.

7.

MARKETING AUTHORISATION HOLDER Amdipharm UK Limited Dashwood House, 69 Old Broad Street, London, EC2M 1QS, United Kingdom

8.

MARKETING AUTHORISATION NUMBER PL 20072/0010

9.

DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION Date of first authorisation: 05 December 2005 Date of latest renewal: 31 October 2008

10.

DATE OF REVISION OF THE TEXT January 2024